Klupczynska Agnieszka, Dereziński Paweł, Matysiak Jan, Dyszkiewicz Wojciech, Kasprzyk Mariusz, Kokot Zenon J
Department of Inorganic and Analytical Chemistry, Poznan University of Medical Sciences, 60-780 Poznan, Poland.
Department of Thoracic Surgery, Poznan University of Medical Sciences, Szamarzewskiego 60-569 Poznan, Poland.
Biomed Pharmacother. 2017 Apr;88:1031-1037. doi: 10.1016/j.biopha.2017.01.141. Epub 2017 Feb 7.
The aim of the study was to identify significant abnormalities in angiogenic factor profiles occurring at early-stage non-small cell lung cancer (NSCLC). Contrary to the previous studies, our research included patients with only stage I NSCLC, which allowed for estimating the utility of circulating angiogenic factors in early NSCLC detection. The investigation was performed in serum samples collected from individuals with untreated NSCLC (n=41) and a matched control group of healthy individuals (n=61). All patients had histopathologically-confirmed stage IA or IB NSCLC. Serum concentrations of 16 angiogenesis markers comprising growth factors, receptors, cytokines, chemokines and hormones, were measured using a bead-based multiplex immunoassay. Among the determined proteins, osteopontin, platelet-derived growth factor-AB and -BB (PDGF-AB/BB) and hepatocyte growth factor (HGF) demonstrated the largest increase in concentration in NSCLC patients as compared with the non-cancer group. ROC curve analysis confirmed their high discriminatory abilities in detection of early NSCLC (AUC=0.809, 95%CI 0.725-0.881). Serum levels of the studied angiogenic factors differed slightly between patients with lung adenocarcinoma and squamous cell carcinoma. The study demonstrated that osteopontin, PDGF-AB/BB, and HGF might add up to the methods used in NSCLC diagnosis. Future research should address the question about their specificity and performance in early NSCLC detection in a combination with various putative lung cancer markers.
该研究的目的是确定早期非小细胞肺癌(NSCLC)中血管生成因子谱的显著异常。与先前的研究相反,我们的研究仅纳入了I期NSCLC患者,这有助于评估循环血管生成因子在早期NSCLC检测中的效用。研究在从未经治疗的NSCLC患者(n = 41)和匹配的健康个体对照组(n = 61)采集的血清样本中进行。所有患者均经组织病理学确诊为IA期或IB期NSCLC。使用基于微珠的多重免疫测定法测量了16种血管生成标志物的血清浓度,这些标志物包括生长因子、受体、细胞因子、趋化因子和激素。在测定的蛋白质中,骨桥蛋白、血小板衍生生长因子AB和BB(PDGF-AB/BB)以及肝细胞生长因子(HGF)与非癌症组相比,在NSCLC患者中的浓度升高最为显著。ROC曲线分析证实了它们在检测早期NSCLC方面具有较高的鉴别能力(AUC = 0.809,95%CI 0.725 - 0.881)。肺腺癌和鳞状细胞癌患者之间,所研究的血管生成因子的血清水平略有差异。该研究表明,骨桥蛋白、PDGF-AB/BB和HGF可能会补充到NSCLC诊断所使用的方法中。未来的研究应解决它们与各种假定的肺癌标志物联合用于早期NSCLC检测时的特异性和性能问题。